The global health community is facing a significant challenge with the rapid spread of multidrug-resistant Gram-negative organisms. These organisms have developed various mechanisms to evade the effects of commonly prescribed antibiotics, making it increasingly difficult to treat infections caused by them. Of particular concern is the rise in carbapenemase-producing organisms (CPO), which are capable of spreading their carbapenemase genes through mobile genetic elements. This poses a serious threat as there are limited treatment options for infections caused by CPO, and the mortality rates associated with these infections are high. Identifying whether an organism is carbapenemase-producing and determining the class of carbapenemase(s) it produces is crucial for treatment decisions. Certain antibiotics have better activity against specific carbapenemases, making accurate detection important. Additionally, CPO can spread more easily between patients compared to non-CP-carbapenem-resistant organisms, necessitating stricter infection control measures. Currently, there are several phenotypic assays used in clinical practice to detect CPO. These include growth-based assays, hydrolysis methods, and lateral flow immunoassays. While no single test meets all the ideal specifications, there are user-friendly, affordable, accurate, and feasible tests available for implementation in clinical microbiology laboratories of all sizes. In conclusion, addressing the challenge of multidrug-resistant Gram-negative organisms, particularly carbapenemase-producing organisms, requires a comprehensive understanding of their mechanisms, accurate detection methods, and effective infection control measures.